Chiesi has been developing medicines to treat respiratory disease for more than 30 years, including therapies for asthma and chronic obstructive pulmonary disease (COPD).
Chiesi has been deeply committed to Neonatology for over 30 years. Working alongside the medical community and investing in Neonatal Research & Development, Chiesi has the ultimate mission to offer innovative and effective treatment options to improve the level of care for preterm babies....
In 2020, Chiesi launched Chiesi Global Rare Diseases, a business unit focused on supporting people living with rare diseases.
The Global Rare Diseases unit works in collaboration with the wider Chiesi Group to harness the full resources and capabilities of our global...
Transplantation is a therapy area to which Chiesi are fully committed.
Chiesi has developed a range of medicines across a number of therapy areas including rheumatoid arthritis (RA), osteoarthritis, ankylosing spondylitis (AS) and cardiovascular disease.
-
-
Our research and development activity is headquartered in Parma, Italy. Additionally, there are six other major research centers located in Chippenham (UK), Paris (France), Cary (USA), Lidingo (Sweden), Shanghai (China), and Toronto (Canada).
Our research and development...
Chiesi is a research-focused biopharmaceuticals group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care.
Our founder, Giacomo Chiesi, dreamed of driving cutting-edge research...
Chiesi operates against a shared value mission; making decisions based on what is best for our business, patients, people and planet.
We work with integrity, balancing business prosperity with...
Our Commitment
Within the Chiesi group, social obligation is central to our mission statement. In addition to providing medicines we support various patient organisations, and our employees are involved in diverse social and community projects.
The Chiesi...
Purpose of this privacy notice
Chiesi Limited (collectively referred to as “Chiesi”, “we”, “us” or “our” in this privacy notice) respects your privacy and is committed to protecting your personal data. This privacy notice...
-
Directions
For information on where to find us please click here
Medical Information and Medical Science Liaison Support
If you are a healthcare professional, practicing in...
Our culture is what enables us to deliver outstanding growth and provide the greatest value for our business, patients, people and planet. At Chiesi, we focus on finding innovative solutions and embracing new challenges.
Every choice we make is driven by the concept of...
Pharmacovigilance
Chiesi has a system for pharmacovigilance for medicines that are marketed or under clinical development. We take action where necessary to ensure that the safety of our medicines is continuously...
-
-
-
To be confirmed
The following list includes some of Chiesi's products that are available in the UK. Please visit http://www.medicines.org.uk/emc/ for more information.
For the UK: Adverse events should be reported. Reporting forms and information can be found...
Commitment to transparency
Chiesi provides health care professionals, health care organisations and patients with clear information about the proper use of the medicines and devices we manufacture.
We are committed to disclosing...
RECRUITMENT PRIVACY NOTICE
What is the purpose of this document?
Chiesi Limited (“Chiesi”) is a "data controller". This means that we are responsible for deciding how we hold and use personal information about you. You are being sent a copy of this...
Finding the hidden millions: restoration of early COPD diagnosis for Hull Lung Health Check participants to optimise treatment and improve outcomes
Chronic obstructive pulmonary disease, or...
PURPOSE
Our Terms of Use, together with any documents referred to in them, set out the terms on which you may make use of this website. By using our website, you confirm you have read, understood and agree to be bound by these terms of use. If you do not agree you must not use...
-
-
-
-
Introduction and aim
Chiesi Limited (“Chiesi”) operates from two main sites in the UK, Manchester and Chippenham.
Chiesi is dedicated to the research, development and sales of innovative, therapeutic prescription medicines in the field of respiratory,...
The climate crisis is a health crisis, and businesses have a significant role to play in addressing this global challenge.
At Chiesi, sustainability is at the heart of our commitment to act as a force for good. It is reflected in our way of doing business, in the way we...
We live in a time of great changes. The planet is exploited beyond its limits and its equilibriums are in continuous transformation. We ourselves have changed the way we live and imagine our society. The fragile and vulnerable pay the price: those who are often left...
As a B Corp in the biopharmaceutical industry, Chiesi is counted among businesses that are leading a global movement for an inclusive, equitable, and regenerative economy. It is an achievement to be proud of, and yet one that feels natural: caring for others lies at the root of health science...
Our commitment to a sustainable future
Sustainability is a core belief of Chiesi. In 2019, we announced our commitment to becoming carbon neutral by 2035 as well as reducing the carbon footprint of our activity and portfolio.
As a certified...
PROTECTING PATIENTS AND THE PLANET
At Chiesi, we believe true ‘sustainability’ in respiratory care can only be achieved with a broad array of projects that protect both our patients and the planet. This holistic approach means we sometimes see things a little differently than...
The United Nations Global Compact defines supply chain sustainability as "the management of environmental, social and economic impacts and promotion of good governance practices throughout the entire life cycle of goods and...
Research on lung health often looks at the health of people with lung conditions in limited ways. It mainly focusses on the illness itself and available...
Our Commitment
Within the Chiesi group, social obligation is central to our mission statement. In addition to providing medicines we support various patient organisations, and our employees are involved in diverse social and community projects.
The Chiesi...
Working in partnership
Chiesi is working in collaboration with the NHS and external stakeholders to ensure that Chiesi understands the needs of health care professionals, patients, and the environment that we are working in. This enables Chiesi’s activities to be aligned to NHS...
Chiesi is committed to collaborative working that either enhances patient care, is for the benefit of patients, or alternatively must benefit the NHS and as a minimum maintain patient care.
We are interested in collaborating with eligible organisations to support projects that pool the...
Every year more than 70 million inhalers are prescribed in the UK annually, and the majority are disposed of in household waste without being recycled.1
Re-Hale was a collaborative working project with NHS Kent and Medway ICB,...
NTEC - Neonatology Technology Enabled Care
The Northwest is the third most populated region in the UK with a population of 6.1 million, and a birth rate of about 77,500 annually. Each year,...
Asthma is a significant health concern in Blackpool, where over 1,200 of the approximately 16,100 patients registered at Bloomfield Medical Centre have a confirmed diagnosis of asthma.1 Blackpool is an area of high levels of...
Over five million people in the UK have asthma, and 1.4 million are living with chronic obstructive pulmonary disease (COPD).1,2
Estimates suggest that only 30% of people living with asthma, and less than 20% of people living with COPD in the UK...
Chronic obstructive pulmonary disease (COPD) is one of the most common respiratory conditions in the UK, with a patient population of 1.4 million.1 In total, one in four people with COPD wait more than five years to be diagnosed with COPD and one in eight wait more than...
Chronic obstructive pulmonary disease (COPD) is a term used to describe long-term bronchitis and emphysema. It is a common, life-long and often severe condition caused by damage to the lungs and can lead to breathlessness, wheezing and coughing. A single COPD exacerbation...
AIR - Take Action for Inhaler Recycling
An estimated 73 million inhalers are prescribed in the UK each year, which accounts for around 3% of total NHS UK emissions.1
Inhalers that are disposed of...
The Chiesi UK LinkedIn and Facebook pages are designed for sharing information, news and events relating to the world of health or to Chiesi. We are delighted that you are in touch with us on these channels and hope that we can develop a fruitful and...
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
SPC - Cardioplen XL® 2.5mg
SPC - Cardioplen XL® 5mg
SPC - Cardioplen XL® 10mg
PIL
SPC - Clenil® Modulite® 50mcg (with Dose Indicator) SPC - Clenil® Modulite® 100mcg (with Dose Indicator) SPC - Clenil® Modulite® 200mcg (with Dose Indicator) SPC - Clenil® Modulite® 250mcg (with Dose Indicator)
PIL...
SPC
PIL
SPC
PIL
SPCPIL
SPC
PIL
SPC
PIL
SPC
PIL
SPC
PIL
SPC
PIL
SPC PIL
SPC
PIL
SPC
PIL
SPC
PIL
SPC
PIL
SPC
PIL
SPC
PIL
SPCPIL
SPC - Ferriprox® 500mgSPC - Ferriprox® 1000mgSPC - Ferriprox® 100mg/ml oral solutionPIL - Ferriprox® 500mgPIL - Ferriprox® 1000mgPIL - Ferriprox® 100mg/ml oral solution
SPC
PIL
SPC
PIL
SPC PIL
SPC PIL
SPC
PIL
SPC
PIL
SPC
PIL
SPC
PIL
SPC
PIL
